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Genetic background of a mouse strain determines its susceptibility to disease. C57BL/6J and 39 
Balb/CJ are two widely used inbred mouse strains that we found react dramatically differently to 40 
angiotensin II and high-salt diet (AngII+Salt). Balb/CJ show increased mortality associated with 41 
anuria and edema formation while C57BL/6J develop arterial hypertension but do not 42 
decompensate and die. Clinical symptoms of heart failure in Balb/CJ mice gave the hypothesis 43 
that AngII+Salt impairs cardiac function and induces cardiac remodelling in male Balb/CJ, but 44 
not in male C57BL/6J mice. To test this hypothesis, we measured cardiac function using 45 
echocardiography, before treatment and every day for seven days during treatment with 46 
AngII+Salt. Interestingly, pulsed wave Doppler of pulmonary artery flow indicated increased 47 
pulmonary vascular resistance and right ventricle systolic pressure in Balb/CJ mice, already 24 48 
hours after starting AngII+Salt treatment. In addition, Balb/CJ mice showed abnormal diastolic 49 
filling indicated by reduced early and late filling and increased isovolumic relaxation time. 50 
Further, Balb/CJ exhibited lower cardiac output compared to C57BL/6J even though they 51 
retained more sodium and water, as assessed using metabolic cages. Left posterior wall thickness 52 
increased during AngII+Salt treatment but did not differ between the strains. In conclusion, 53 
AngII+Salt treatment causes early restriction of pulmonary flow, reduced left ventricular filling 54 
and cardiac output in Balb/CJ, which results in fluid retention and peripheral edema. This makes 55 
Balb/CJ a potential model to study the adaptive capacity of the heart for identifying new disease 56 
mechanisms and drug targets.  57 
 58 
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Heart failure is one of the leading causes of death worldwide (26) and is characterized by 63 
insufficient cardiac output, required for normal tissue function, because of impaired relaxation 64 
and thereby filling and/or contraction (11). Typical signs of heart failure are dyspnea, reduced 65 
exercise tolerance, fatigue and edema (20). C57BL/6J and Balb/CJ are two widely used inbred 66 
mouse strains that we accidently found react dramatically differently to a combination of 67 
angiotensin II and high-salt diet (AngII+Salt). Balb/CJ mice develop massive edema within 4-6 68 
days of treatment associated with substantial mortality. C57BL/6J on the other hand develop 69 
arterial hypertension and some renal damage as previously shown, but do not decompensate or 70 
die (6). It is interesting to note that Balb/CJ has been found to be more susceptible to a number of 71 
diseases and syndromes in the literature, some have been directly tied to differences in T-cell 72 
mediated innate immunity (8, 13), others to increased oxidative stress (7). Given that the 73 
symptoms of high mortality and edema are indicative of heart failure, it is interesting to note that 74 
Balb/CJ has been found to be more sensitive to heart disease in a number of different models (12, 75 
17, 24), but the very fast apparent decompensation after combined AngII and high dietary salt has 76 
not been reported previously and the mechanism is unknown. 77 
 78 
Currently, there are many chronic heart failure models, but very few that show this kind of rapid 79 
deterioration (11). It is therefore of interest to study the cardiovascular response to AngII and 80 
high-salt diet in Balb/CJ mice, which could potentially work as a model of acute decompensation. 81 
Acute decompensation of heart failure refers to new or worsening signs and symptoms of heart 82 
failure, such as dyspnea and congestion, which rapidly escalates and requires urgent treatment 83 
(19). Diagnosis of acute decompensated heart failure is associated with high mortality and 84 




In a previous study, focusing on the renal response to AngII and high-salt diet in Balb/CJ and 87 
C57BL/6J, we found that Balb/CJ mice retain more sodium and water compared to C57BL/6J 88 
mice (14). However, we did not find any systematic effects on glomerular filtration rate, 89 
indicating that severe renal failure is probably not the cause of the high mortality. Considering 90 
the clinical symptom of heart failure in Balb/CJ mice, we hypothesized that AngII and high-salt 91 
diet impairs cardiac function and induces cardiac remodelling in Balb/CJ, but not in C57BL/6J 92 
mice. To test this hypothesis, cardiac systolic and diastolic function were measured, as well as 93 
pulmonary artery flow, blood pressure, and ventricular and atrial weight. Further, fluid balance 94 
was assessed to validate the previous findings of increased sodium and water retention in Balb/CJ 95 











Male BALB/cJBom (Balb/CJ) and C57BL/6J mice at 6 weeks-of-age were used in the 105 
experiments (Taconic, Denmark). Animals were treated in accordance with NIH guidelines for 106 
treatment of experimental animals, and the protocol was approved by committees for animal 107 
experiments at University of Bergen and Uppsala. Animals were housed at 20-25°C, 45-50% 108 
humidity, 12/12 hours light/dark cycle, with free access to food and water. They were fed 109 
standard pelleted food with 0.27-0.3% sodium, or high-salt diet with 3% or 4% sodium (Special 110 
Diets Services, Witham, UK). 111 
 112 
Study design and treatment 113 
Mortality frequency from the preliminary study was included in a previous publication (14), but 114 
time-to-event data was deemed important in relation to present study of the decompensation time-115 
course. In the preliminary study sham operated animals and animals treated with a combination 116 
of 1 µg/min/kg angiotensin II (AngII) and 4% sodium diet for five weeks were used. AngII 117 
(Sigma-Aldrich) or saline was infused using subcutaneous osmotic minipumps implanted under 118 
isoflurane anaesthesia (1007D, Alzet, Cupertino, CA). Buprenorphine (0.05-0.1 mg/kg) was used 119 
for analgesia. Blood pressure was measured before treatment and five weeks after treatment or 120 
before euthanasia in edematous mice. 121 
 122 
In the follow-up study, animals were treated with 0.5 µg/min/kg AngII and 3% sodium diet for 123 
seven days. High mortality in the preliminary study necessitated lower dose in this study to be 124 
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able to investigate the underlying pathophysiology. Before treatment, baseline sodium and fluid 125 
balance, blood pressure measurement and echocardiography were performed. Thereafter, blood 126 
pressure measurement and echocardiography were performed every day for seven days; the first 127 
measurements performed 24 hours after treatment initiation. Sodium and fluid balance were 128 
measured in treated Balb/CJ mice when >20% reduction in cardiac output was estimated with 129 
echocardiography or when symptoms of decompensation indicated the need for euthanasia. To 130 
balance the experimental groups, every time fluid and sodium balance was measured in one 131 
Balb/CJ mouse, fluid and sodium balance was measured in one randomly picked C57BL/6J 132 
mouse. For the same reason, every time a Balb/CJ mouse died or had to be euthanized, a 133 
randomly picked C57BL/6J mouse was euthanized as well.  134 
 135 
Tail-cuff blood pressure 136 
Blood pressure was measured with tail-cuff after warming the animals at 32°C (CODA-6, Kent 137 
Scientific, Torrington, CT). Before the blood pressure measurements were performed, the 138 
animals were allowed to acclimatize to the tube, by keeping them in the tube covered with a dark 139 
blanket for 10-15 min. Three acclimatization cycles were followed by five measurement cycles 140 
for each animal. The five measurement cycles were averaged to obtain systolic and diastolic 141 
blood pressure, and heart rate for that animal. 142 
 143 
Echocardiography 144 
Echocardiography was performed under light isoflurane anaesthesia (0.9%) for maximum of 15 145 
minutes using Vevo1100 ultrasound (Visual Sonics, Canada). Cardiac output, stroke volume, 146 
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ejection fraction and heart rate were quantified in parasternal long-axis view. Left ventricle 147 
posterior wall thickness was measured by M-mode positioned at the largest diameter in 148 
parasternal long-axis view, carefully avoiding inclusion of the papillary muscle. Mitral valve 149 
flow and pulmonary artery flow were assessed with Pulsed wave Doppler. 150 
 151 
Fluid and sodium balance 152 
Water and food intake, and urine excretion were measured for 24 hours using metabolic cages 153 
(MMC100, Hatteras Instruments, NC). To reduce the stress associated with metabolic caging, the 154 
upper part of the metabolic cages were covered in black plastic film. Sodium was measured in 155 
urine collected with metabolic cages, using flame photometry (Instrumentation Laboratory, 156 
Massachusetts, USA). 157 
 158 
Lung water content and heart weight 159 
Lung tissue was blotted dry, weighed and dried at 67°C for 16 hours. The heart was excised, left 160 
and right atria, and left and right ventricle dissected and weighed.  Heart weight was corrected for 161 
tibia length. 162 
 163 
Statistical analysis 164 
Results are shown as mean ± standard error (SEM). Data obtained from multiple independent 165 
groups were analyzed using two-way ANOVA and Tukey’s post-hoc test.  Data not fulfilling the 166 
assumption of independency were analyzed with linear mixed effects model using a restricted 167 
maximum likelihood fit. Individual contrasts of least-squares means were adjusted using Tukey’s 168 
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method. p<0.05 was accepted as significant. Kaplan-Meier survival analysis was performed using 169 
death or premature sacrifice as end-point censoring animals euthanized at experiment completion.  170 
 171 
Results 172 
Balb/CJ show increased mortality after treatment with AngII and high-salt diet 173 
In the preliminary study, Balb/CJ and C57BL/6J mice were treated with a combination of 174 
1µg/kg/min AngII and 4% sodium diet (AngII+Salt). No AngII+Salt treated Balb/CJ survived the 175 
full 37 day-experiment. They developed significant subcutaneous edema on the breast, forepaws 176 
and neck and had to be sacrificed (Figure 1A left). In addition, ascites was noted in several 177 
Balb/CJ at sacrifice, and many of the animals were anuric. In contrast, 90% of C57BL/6J mice 178 
survived without symptoms (Figure 1A right). Blood pressure did not increase in Balb/CJ mice 179 
treated with AngII+Salt, however, some mice developed hypotension (Figure 1B). C57BL/6J on 180 
the other hand developed hypertension. In summary, these early experiments showed that 181 
Balb/CJ were significantly more sensitive to AngII+Salt than C57BL/6J, and appeared to develop 182 
acute decompensation. High morbidity and fast progression in Balb/CJ necessitated less intense 183 
treatment (AngII 0.5 µg/kg/min and 3% sodium) and shorter follow-up to investigate the 184 
physiological mechanisms reproducibly. Therefore, in all following experiments the AngII dose 185 
was reduced to 0.5 µg/kg/min and sodium content in food to 3%. Mortality data presented in this 186 
paper have previously been used in a meta-analysis to estimate the overall effect of AngII+Salt 187 
on mortality in Balb/CJ and C57BL/6J (14). However, time-to-event mortality data are presented 188 




Cardiac output decreases in Balb/CJ and increases in C57BL/6J in response to AngII+Salt 191 
treatment 192 
To study the sequence of circulatory dysfunction Balb/CJ and C57BL/6J mice were treated with 193 
AngII+Salt for seven days. Echocardiography was performed before the treatment was started 194 
and every day during the seven day treatment period. During AngII+Salt treatment Balb/CJ mice 195 
had lower cardiac output compared to C57BL/6J mice (Figure 2A). This difference was apparent 196 
at day 3 and the mice started dying or had to be sacrificed because of edema from day 4. Reduced 197 
cardiac output was not caused by decreased systolic function since ejection fraction did not differ 198 
between the strains and was quite constant over time (Figure 2B). Balb/CJ had lower stroke 199 
volume compared to C57BL/6J (Figure 2C), without a compensatory increase in heart rate 200 
(Figure 2D).  201 
 202 
AngII+Salt causes abnormal left ventricle filling in Balb/CJ mice 203 
A decrease in cardiac output in Balb/CJ was a consequence of reduced filling, as can be seen as 204 
lower end-diastolic and end-systolic volume over time (Table 1). To asses filling of the heart and 205 
thereby diastolic function, mitral valve flow was measured with pulsed wave Doppler. 206 
Interestingly, passive filling (Peak E, Figure 3A, 3D) was higher in Balb/CJ than in C57BL/6J at 207 
baseline, resulting in a higher E/A ratio (Figure 3C). Both passive and active filling (Peak A, 208 
Figure 3B) of the left ventricle were reduced in Balb/CJ over time, while isovolumic relaxation 209 
time increased (Table 1), indicating abnormal diastolic function. This reduction was seen already 210 
at day 2, thus preceding reduction in cardiac output. 211 
 212 
AngII+Salt increases pulmonary and systemic vascular resistance in Balb/CJ  213 
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Pulmonary artery flow acceleration time to ejection time ratio (AT/ET), measured by pulsed 214 
wave Doppler has been shown to estimate right ventricle pressure and thereby pulmonary 215 
pressure in a reliable and reproducible way (31). Lower AT/ET correlates with higher right 216 
ventricle and pulmonary artery pressure. Pulmonary AT/ET decreased in Balb/CJ already at day 217 
1, thus 24 hours following treatment initiation (Figure 4A). Systolic blood pressure (Figure 5A) 218 
and mean arterial blood pressure (Figure 5C) increased at day 2 in Balb/CJ mice, but not in 219 
C57BL/6J. AngII+Salt treatment had different effect on systolic- and diastolic blood pressure, 220 
and mean arterial blood pressure over time in Balb/CJ compared to C57BL/6J (Figure 5 A-C). 221 
Interestingly, Balb/CJ had lower heart rate both at baseline and during treatment (Figure 5D). 222 
Increased pulmonary pressure as well as systemic blood pressure indicates an increase in vascular 223 
resistance in Balb/CJ during AngII+Salt treatment. Balb/CJ mice did not develop pulmonary 224 
edema (Table 2) indicating that the increase in pulmonary pressure is primary and not a result of 225 
left ventricle diastolic dysfunction.  226 
 227 
AngII+Salt induces left ventricle hypertrophy both in Balb/CJ and C57BL/6J mice 228 
Left ventricle posterior wall thickness, measured by M-mode in parasternal long-axis view, 229 
increased in both strains during AngII+Salt treatment (Table 1), indicating left ventricle 230 
remodelling. Left ventricle and right ventricle weight after treatment did not differ between the 231 
strains (Table 2). However, there was a tendency to higher right atrium weight in Balb/CJ mice, 232 
which may indicate fluid congestion and increased right ventricular pressure as would be 233 
expected in pulmonary hypertension.  234 
 235 
AngII+Salt treated Balb/CJ retain more sodium and water compared to C57BL/6J 236 
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Fluid and sodium balance was measured in Balb/CJ and C57BL/6J before treatment and when 237 
decompensation could be detected through symptoms or as reduced cardiac output by 238 
echocardiography. Urine and sodium excretion was lower in AngII+Salt treated Balb/CJ mice 239 
compared to AngII+Salt treated C57BL/6J mice (Figure 6). Food (Balb/CJ 2.72±1.01 g, 240 
C57BL/6J 6.78±1.64 g) and water intake (Balb/CJ 4.83±1.74 ml, C57BL/6J 10.75±6.78 ml) was 241 
slightly higher in C57BL/6J, although not significantly.  Ratio of excreted urine to water intake 242 
was higher in C57BL/6J (0.65±0.08 vs 0.26±0.08). Some Balb/CJ mice did not excrete any urine 243 
at all during the 24-hour measurement period, which is indicative of acute kidney injury and 244 
potentially cardio-renal syndrome.  245 
 246 
Discussion 247 
The main finding of this study is that the decompensation of Balb/CJ mice treated with 248 
AngII+Salt follows initially higher systemic and increased pulmonary artery pressure, associated 249 
with cardiac hypertrophy, abnormal left ventricle filling and lower cardiac output compared to 250 
C57BL/6J mice. C57BL/6J mice on the other hand develop hypertension and cardiac 251 
hypertrophy, with low mortality and absence of edema. The results confirm our hypothesis that 252 
AngII+Salt impairs cardiac function and induces cardiac remodelling in Balb/CJ mice.  253 
 254 
Already 24 hours following treatment initiation, a difference in pulmonary artery AT/ET was 255 
seen between the strains. Balb/CJ mice had lower pulmonary AT/ET indicating higher pulmonary 256 
pressure. Interestingly, Balb/CJ has previously been shown to be more susceptible to pulmonary 257 
vascular muscularization when exposed to cigarette smoke, which may be connected to increased 258 
susceptibility to pulmonary hypertension (22). Balb/CJ mice also had higher systemic systolic 259 
blood pressure compared to C57BL/6J mice. Increase in systemic and pulmonary blood pressure 260 
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indicates increased overall responsiveness to angiotensin II in this strain. The increase in overall 261 
responsiveness may be a result of increased expression of angiotensin II Type I Receptors 262 
(AT1R) or decreased expression of angiotensin II Type II Receptors (AT2R), the latter suggested 263 
to have vasodilatory effects (29, 32). Further, Balb/CJ may have a reduced ability of metabolizing 264 
angiotensin II, either by converting angiotensin II to Ang 1-7 or by internalizing the angiotensin 265 
II bound AT1R (3, 23). Angiotensin II has also been shown to stimulate release of endothelin-1, 266 
which plays a major role in pulmonary hypertension (4, 5). Whether any of these mechanisms is 267 
responsible for the exacerbated phenotype in Balb/CJ mice needs to be addressed in future 268 
studies.  269 
 270 
Balb/CJ mice also show abnormal diastolic filling during AngII+Salt treatment. Similarly, left 271 
ventricular diastolic dysfunction is seen in patients with idiopathic pulmonary hypertension, 272 
characterized by reduced end-diastolic and end-systolic volume, reduced peak E and E/A ratio 273 
and increased isovolumic relaxation time (15). Patients with primary heart failure with preserved 274 
ejection fraction also show reduced peak E, E/A ratio and increased isovolumic relaxation time, 275 
although increased end-diastolic and end-systolic volume (15). It is important to note that this 276 
model was not initially designed to be similar to human disease, but is originally an interesting 277 
difference between two common mouse strains. However, we would like to stress that there are 278 
similarities to human pulmonary hypertension and acute decompensation.  279 
 280 
Balb/CJ mice treated with AngII+Salt had lower cardiac output compared to C57BL/6J mice. 281 
Interestingly, Balb/CJ had lower cardiac output even though they had higher sodium and water 282 
reabsorption, which should increase blood volume, venous return and cardiac output (2, 27). 283 
Increased fluid reabsorption is a common finding in patients with pulmonary hypertension and 284 
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heart failure with preserved ejection fraction (16, 28). However, the increased sodium and water 285 
reabsorption in this model may be aggravated by an enhanced action of angiotensin II on the 286 
kidneys to stimulate sodium retention. Angiotensin II is also known to stimulate release of 287 
aldosterone, which further increases sodium retention (21). Whether angiotensin II stimulated 288 
aldosterone release differs between the strains needs further exploration in future studies.    289 
 290 
Sodium and urine excretion were measured as 24-hour collections using metabolic cages. The 291 
method has some limitations since mice can be sloppy drinkers and some of the urine will 292 
evaporate during the collection period. However, high salt diet increases urine excretion, thereby 293 
reducing the role of urine evaporation in the treated groups, and 24-hour urinary biochemistry 294 
assessed using metabolic cages is similar in Balb/CJ and C57BL/6J (21). Metabolic caging is a 295 
stressful situation for the animals, evident by the decreased weight in both strains by day 1, which 296 
in turn may affect sodium and urine excretion. Even though the metabolic cages were covered 297 
with black plastic film to reduce the stress, the stress associated with metabolic caging is the 298 
major limitation of sodium and fluid balance measurements. In addition, the surgery to implant 299 
the osmotic minipump is an additional stressor and probably contributes to the initial weight 300 
decrease. Interestingly, stress seems to be part of the model as we find slightly improved survival 301 
in animals that do not undergo as many investigations, for example the animals used for earlier 302 
microarray experiments (14).  303 
 304 
Angiotensin II is known to induce cardiac hypertrophy irrespective of its effect on systemic blood 305 
pressure (1, 18). Interestingly, AngII+Salt induces left ventricle remodelling in both strains as 306 
indicated by increased left ventricle posterior wall thickness, but only one of them 307 
decompensates. Cardiac hypertrophy is a compensatory mechanism for increased work load, but 308 
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the molecular pathway for induction of hypertrophy, cell death and fibrosis are similar. As a 309 
consequence, small changes in the molecular pathway may result in heart failure instead of 310 
physiological cardiac remodelling (10). One such pathway is the TGFβ signalling pathway which 311 
may stimulate hypertrophic growth via TGFβ activated kinase 1 (TAK1) or induce apoptosis and 312 
heart failure via small mothers against decapentaplegic (SMADs) signalling (9, 10). Thus, 313 
angiotensin II may be stimulating slightly different signalling pathways in Balb/CJ and 314 
C57BL/6J, which results in decompensation in Balb/CJ and compensation in C57BL/6J.  315 
 316 
Reduced cardiac function in Balb/CJ is corroborated by the clinical finding of edema. However, 317 
the reduction of cardiac output estimated in our data does not appear severe enough to be 318 
uniformly lethal. This may indicate additional contributing mechanisms, but may equally well be 319 
hidden because of limitations inherent to the model and design. Anesthesia is necessary for the 320 
accurate measurement of mouse cardiac function with ultrasound, but anesthesia also reduces 321 
sympathetic drive and may thus mask some of the differences between the strains. Further, as the 322 
mice start to decompensate they no longer tolerate anesthesia, much like in human pulmonary 323 
hypertension (30), so there is a limit to how ill the mice can be before the number of animals lost 324 
to investigation becomes unacceptable for ethical reasons. Finally, the time resolution of our 325 
measurements, at once per day, may be too low to detect the final progression of decompensation 326 
and a continuous telemetric approach may be warranted in future studies. 327 
 328 
In conclusion, AngII+Salt treatment causes early restriction of pulmonary flow, reduced left 329 
ventricular filling and cardiac output in male Balb/CJ, which results in fluid retention and 330 
peripheral edema. The pattern of peripheral edema, unchanged lung fluid, and diastolic left 331 
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ventricular failure is most indicative of right ventricular failure, which is consistent with 332 
pulmonary hypertension and fluid overload as the precipitating mechanisms. C57BL/6J on the 333 
other hand do not show this aggravated phenotype, indicating that there is a genetic difference 334 
between these strains, which makes Balb/CJ more sensitive to treatment with AngII+Salt. In 335 
future studies, male Balb/CJ may be used as a model to study the adaptive capacity of the heart, 336 
which may help us identify new disease mechanisms and drug targets.  337 
 338 
Perspective and significance  339 
Some patients are more prone to circulatory decompensation with the same injury or pathology. 340 
However, the reasons for this are not entirely clear but may include genetic predisposition, and 341 
unappreciated differences in the underlying pathophysiology. Decompensation is a complex 342 
process where cardiac overload and fluid congestion leads to progressive heart failure. The 343 
hormone angiotensin II (AngII) is known to play a role in vascular contractility, salt and fluid 344 
retention as well as cardiac contractility. This paper describes a new model of critical circulatory 345 
decompensation in Balb/CJ mice treated with a combination of AngII and high-salt diet with 346 
signs of early pulmonary flow restriction as in vasoreactive pulmonary hypertension. On the 347 
other hand, the mouse strain C57BL/6J is resistant to this treatment. As a new animal model this 348 
provides a new setting in which to study factors that predispose to pulmonary vasoconstriction, 349 
fluid retention and cardiac decompensation. In addition, the naturally occurring genetic variation 350 
between Balb/CJ and C57BL/6J may be used to identify novel genetic determinants for these 351 
phenotypes. Further, pulmonary hypertension after AngII suggests that clinical use of AngII as a 352 
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Table legends 449 
Table 1. Echocardiographic measurements in Balb/CJ and C57BL/6J 450 
Echocardiographic measurements were obtained during control period (Day 0) and every day 451 
during treatment with angiotensin II and 3% sodium diet (day 1-7). AET = Left ventricle ejection 452 
time. IVCT = Left ventricle isovolumic contraction time. IVRT = Left ventricle isovolumic 453 
relaxation time. cIVRT = corrected isovolumic relaxation time. IVRT was corrected for 454 
differences in heart rate by using formula IVRT/square root of RR interval. MPI = myocardial 455 
performance index calculated from (IVRT+IVCT)/AET. MV decal T = Mitral valve deceleration 456 
time. PA Peak Vel = Pulmonary artery peak velocity. ESV = End-systolic volume. EDV = End-457 
diastolic volume. LVPW = Left ventricle posterior wall thickness. * indicates p < 0.05 treatment 458 
vs. control within strain. # indicates p < 0.05 between strains with same treatment. 459 
 460 
Table 2. Heart weight and lung water content after treatment with angiotensin II and 3% sodium 461 
diet 462 
Heart weight corrected for tibia length. RV = Right ventricle. LV = Left ventricle. S = Septum. 463 
RA = Right atrium.  464 
  465 
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Figure legends 466 
Figure 1.  467 
Pilot study results from Balb/CJ and C57BL/6J mice treated with 1 µg/min/kg AngII and 4% 468 
sodium showing survival (A) and blood pressure measured before treatment and five weeks after 469 
treatment or before sacrifice in edematous mice (B). 10 animals were used in each group. * 470 
indicates p < 0.05 treatment vs. control within strains. # indicates p < 0.05 between strains with 471 
same treatment by two-way ANOVA. 472 
 473 
Figure 2.  474 
Left ventricle systolic function in Balb/CJ and C57BL/6J mice during control (day 0) and 475 
treatment with 0.5 µg/min/kg AngII and 3% sodium (AngII+Salt, day 1-7). AngII+Salt treatment 476 
reduces cardiac output (A) and stroke volume (B) in Balb/CJ over time without effecting ejection 477 
fraction (B) or heart rate (D). 8 Balb/CJ and 8 C57BL/6J mice were used in the experiment, 478 
however, the number of animals decreased after day 4 because of death or euthanasia (see Table 479 
1). Because of low power, animals after day 5 were not included in the statistical analysis. The 480 
data were analyzed with linear mixed effects model and individual contrasts of least-squares 481 
means were adjusted using Tukey’s method. # indicates p < 0.05 between strains with same 482 
treatment. † indicates significant strain difference and ‡ indicates significant interaction of time 483 
and strain. 484 
 485 
Figure 3.  486 
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Left ventricle diastolic function in Balb/CJ and C57BL/6J mice during control (day 0) and 487 
treatment with 0.5 µg/min/kg AngII and 3% sodium (AngII+Salt, day 1-7). Peak E velocity (A), 488 
Peak A velocity (B) and E/A ratio (C) are decreased in treated Blab/CJ mice indicating abnormal 489 
left ventricle filling. (D) shows representative mitral valve flow velocity curve in Balb/CJ and 490 
C57BL/6J before treatment and after treatment. 8 Balb/CJ and 8 C57BL/6J mice were used in the 491 
experiment, however, the number of animals decreased after day 4 because of death or euthanasia 492 
(see Table 1). Because of low power, animals after day 5 were not included in the statistical 493 
analysis. The data were analyzed with linear mixed effects model and individual contrasts of 494 
least-squares means were adjusted using Tukey’s method. * indicates p < 0.05 treatment vs. 495 
control within strains. # indicates p < 0.05 between strains with same treatment. † indicates 496 
significant strain difference and ‡ indicates significant interaction of time and strain. 497 
 498 
Figure 4. 499 
Pulmonary artery flow in Balb/CJ and C57BL/6J mice during control (day 0) and treatment with 500 
0.5 µg/min/kg AngII and 3% sodium (AngII+Salt, day 1-7). Pulmonary artery acceleration time 501 
to ejection time ratio (A) is reduced in Balb/CJ at day 1, indicating increased pulmonary vascular 502 
resistance.  (B) shows representative pulmonary artery flow curve in Balb/CJ and C57BL/6J 503 
before and after treatment. 8 Balb/CJ and 8 C57BL/6J mice were used in the experiment, 504 
however, the number of animals decreased after day 4 because of death or euthanasia (see Table 505 
1). Because of low power, animals after day 5 were not included in the statistical analysis. The 506 
data were analyzed with linear mixed effects model and individual contrasts of least-squares 507 
means were adjusted using Tukey’s method. * indicates p < 0.05 treatment vs. control within 508 
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strains. # indicates p < 0.05 between strains with same treatment. † indicates significant strain 509 
difference and ‡ indicates significant interaction of time and strain. 510 
 511 
Figure 5. 512 
Tail-cuff blood pressure in Balb/CJ and C57BL/6J mice during control (day 0) and treatment 513 
with 0.5 µg/min/kg AngII and 3% sodium (AngII+Salt, day 1-5). AngII+Salt treatment increases 514 
systolic blood pressure (A), diastolic blood pressure (B) and mean arterial blood pressure (C) in 515 
Balb/CJ over time. Heart rate is lower in Balb/CJ compared to C57BL/6J both at baseline and 516 
during treatment. 8 Balb/CJ and 8 C57BL/6J mice were used in the experiment, however, the 517 
number of animals decreased after day 4 because of death or euthanasia (see Table 1). Day 6 and 518 
7 are not shown because of missing data in Balb/CJ during those days. The data were analyzed 519 
with linear mixed effects model and individual contrasts of least-squares means were adjusted 520 
using Tukey’s method. * indicates p < 0.05 compared to control. # indicates p < 0.05 between 521 
strains with same treatment. † indicates significant strain difference and ‡ indicates significant 522 
interaction of time and strain. 523 
 524 
Figure 6.  525 
Fluid and sodium balance in Balb/CJ and C57BL/6J mice treated with 0.5 µg/min/kg AngII and 526 
3% sodium (AngII+Salt). Urine (A) and sodium excretion (B) is lower in AngII+Salt treated 527 
Balb/CJ mice compared to C57BL/6J mice. Number of animals is 4-6 in each group. The data 528 
were analyzed with linear mixed effects model and individual contrasts of least-squares means 529 
22 
 
were adjusted using Tukey’s method. * indicates p < 0.05 compared to control. # indicates p < 530 
0.05 compared to C57BL/6J with same treatment. 531 




Table 1 534 
Balb/CJ Control AngII+Salt 
Day 0  1  2 3 4 5 6 7 
Number alive 8 8 8 8 8 6 2 1 
Weight (g) 25.71±0.26 20.38±1.04* 22.55±1.21* 23.27±0.95* 23.89±1.49 23.95±1.71 20.55±0.75 17.60 
Echocardiography         
AET (ms) 57.85±1.31 57.16±1.30 55.52±1.55 55.14±1.91 53.19±3.29 59.99±4.78 62.28±1.61 64.58 
IVCT (ms) 21.4±1.94# 16.62±1.35# 16.31±2.19 13.77±0.98* 15.31±1.31* 17.23±0.46 17.06±2.39 23.33 
IVRT (ms) 23.49±1.42 27.09±1.51 28.578±1.86 29.50±3.36 32.36±2.36# 40.06±5.67*# 40.39±0.94 39.17 
cIVRT 1.75±0.09 2.07±0.10 2.06±0.10 2.09±0.11 2.38±0.17 2.85±0.44*# 2.59±0.01 2.78 
MPI 0.77±0.05 0.76±0.03# 0.84±0.05 0.80±0.05 0.91±0.08# 0.95±0.03 0.92±0.00 0.97 
MV decel T (ms) 36.20±2.97 42.96±4.75# 43.76±2.72 39.57±2.08# 40.46±3.52# 37.42±2.72 36.33±3.00 27.08 
PA Peak Vel 645.9±44.31 684.54±25.25# 627.25±45.52 658.92±41.47 674.82±40.80 518.31±72.22# 609.23±120.77 466.98 
ESV (µl) 36.61±3.39 35.67±6.09 22.38±4.02* 17.78±3.85* 22.86±5.45* 21.98±2.64 17.42±3.33 16.00 
EDV (µl) 66.21±3.44 66.58±5.70 50.26±3.93* 43.75±5.52* 46.98±5.53* 46.78±3.44* 36.05±3.80 36.34 
LVPW (mm) 0.66±0.03 0.60±0.05# 0.78±0.04 0.92±0.13*# 0.78±0.03 0.83±0.08 0.66±0.13 NA 
C57BL/6J Control AngII+Salt 
Day 0  1  2 3 4 5 6 7 
Number alive 8 8 8 8 8 8 3 2 
Weight (g) 28.70±1.80 22.43±0.96* 26.35±1.69* 26.92±1.40 26.38±1.08* 26.41±1.07* 24.00±0.95 22.80±1.40 
Echocardiography   
AET (ms) 51.94±2.46 54.75±1.35 53.97±1.26 52.20±2.50 53.19±2.85 53.15±1.57 54.40±2.26 45.88±4.49 
IVCT (ms) 16.29±2.20 21.35±1.86 18.28±2.41 15.16±1.25 13.28±0.96 17.54±1.62 18.97±1.59 16.39±0.28 
IVRT (ms) 23.48±2.20 29.40±3.60 28.14±2.03 22.86±0.94 22.71±0.94 26.46±2.45 29.05±4.29 27.64±1.25 
cIVRT 1.92±0.12 2.10±0.20 2.10±0.10 1.83±0.08 1.83±0.06 2.13±0.21 2.19±0.14 2.24±0.04 
MPI 0.80±0.07 0.96±0.10 0.96±0.06 0.78±0.05 0.69±0.04 0.84±0.08 0.88±0.07 0.97±0.06 
MV decel T (ms) 28.52±1.74 34.13±2.11 34.38±1.38 29.47±1.80 29.83±2.44 31.31±2.12 38.33 32.22 
PA Peak Vel 669.92±53.50 485.37±71.97 631.94±39.31 674.71±22.41 787.21±45.56 727.57±73.37 571.65 578.78±80.93 
ESV (µl) 33.39±3.23 40.65±4.47 31.23±2.76 21.06±2.30 21.23±2.95 26.50±3.62 18.77±0.51 24.87±6.71 
EDV (µl) 67.15±3.84 66.71±3.87 61.60±3.82 54.85±2.00 53.33±3.39* 56.05±3.38 45.87±0.88 49.28±5.80 









Table 2 541 
 Balb/CJ C67BL/6J 
Heart weight (mg) 80.90±4.75 72.42±2.84 
Left atria weight (mg) 5.97±1.80 2.86±0.24 
Right atria weight (mg) 10.52±3.49 3.34±0.61 
Left ventricle weight (mg) 53.03±2.38 56.23±2.99 
Right ventricle weight (mg) 12.18±0.70 12.14±1.10 
RV/(LV+S) 0.23±0.02 0.21±0.02  
RA/RV 0.86±0.33 0.29±0.06 
Lung water content (%) 78.46±1.62 76.55±0.46 
 542 
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